Results 341 to 350 of about 263,255 (408)

Randomised, phase 1/2a trial of ION-827359, an antisense oligonucleotide inhibitor of ENaC. [PDF]

ERJ Open Res
Sutharsan S, Fischer R, Gleiber W, Horsley A, Crosby J, Guo S, Xia S, Yu R, Newman KB, Elborn JS.   +9 more
europepmc   +1 more source

Myeloid‐Derived Suppressor Cells in Cancer: Mechanistic Insights and Targeted Therapeutic Innovations

MedComm, Volume 6, Issue 6, June 2025.
This review summarizes the origin and biological characteristics of MDSCs, focusing on their immunological and nonimmunological roles in tumor progression. It also discusses the prognostic value of MDSCs and the latest advancements in clinical trials, highlighting the potential of emerging therapeutic strategies for cancer treatment and drug ...
Tianying Hu, Jianxue Zhai, Zhanda Yang, Jiajia Peng, Chuxuan Wang, Xinyao Liu, Yawen Li, Jiaqi Yao, Fengxi Chen, Haixia Li, Taixue An, Zongcai Liu, Haifang Wang   +12 more
wiley   +1 more source

Antisense Oligonucleotide STK-002 Increases OPA1 in Retina and Improves Mitochondrial Function in Autosomal Dominant Optic Atrophy Cells. [PDF]

Nucleic Acid Ther
Venkatesh A, McKenty T, Ali S, Sonntag D, Ravipaty S, Cui Y, Slate D, Lin Q, Christiansen A, Jacobson S, Kach J, Lim KH, Srinivasan V, Zinshteyn B, Aznarez I, Huryn LA, Li Z, Hufnagel RB, Liau G, Anderson K, Hoger J.   +20 more
europepmc   +1 more source

Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders. [PDF]

Commun Med (Lond)
Lauffer MC, van Roon-Mom W, Aartsma-Rus A, N = 1 Collaborative.   +3 more
europepmc   +1 more source

Construction of a T _m-value prediction model and molecular dynamics study of AmNA-containing gapmer antisense oligonucleotide. [PDF]

Mol Ther Nucleic Acids
Kuroda M, Kasahara Y, Hirose M, Yamaguma H, Oda M, Nagao C, Mizuguchi K.   +6 more
europepmc   +1 more source

Splice-switching antisense oligonucleotide controlling tumor suppressor REST is a novel therapeutic medicine for neuroendocrine cancer. [PDF]

Mol Ther Nucleic Acids
Mishima K, Obika S, Shimojo M.
europepmc   +1 more source

Preclinical and phase I studies of an antisense oligonucleotide drug targeting IGF-1R in liver cancer. [PDF]

Future Oncol
Li Y, Xu Z, Li Y, Jiang T, Meng F, Fu J, Huang L, Wang F, Wang X, Wang F.   +9 more
europepmc   +1 more source

Correction: Antisense oligonucleotide therapy rescues disturbed brain rhythms and sleep in juvenile and adult mouse models of Angelman syndrome.

Elife
Lee D, Chen W, Kaku HN, Zhuo X, Chao ES, Soriano A, Kuncheria A, Flores S, Kim JH, Rivera A, Rigo F, Jafar-Nejad P, Beaudet AL, Caudill MS, Xue M.   +14 more
europepmc   +1 more source